Team:Evry/Description
Page title
Project Description
Cancer cases could rise by 50 % by 2020, with 15 million new cases every year in the world (1). Surgical operation is not a sufficient solution for long-term remission and many cancers are not operable. For example, only 20% of patients with pancreatic cancer have surgically resectable tumors at the time of diagnosis. Among these 20% patients, the vast majority will experience recurrence within the first 2 years (2). Cytotoxic chemotherapy is the the most available treatment for cancer. Unfortunately, the efficacy of chemotherapy is limited and cures are rarely achieved, in particular for solid tumors (3). Little improvement has been made for overall survival with chemotherapy alone. In particular, most chemotherapies kill target cells by triggering a process of programmed cell death and this mode of cell death can be tolerogenic for cancer (3). Second, lymphocyte depletion (lymphopenia) is a common side effect of many anti-cancer drugs. In 2013, immunotherapy was awarded « breakthrough of the year » by Science (4). Immunotherapy consists of inducing the immune system against cancer cells. It is now administered in first line or combined to chemotherapy to overcome its potential immunosuppressive effect. On the contrary of chemotherapy, it can provide a durable effect with improved survival (5). Two strategies are employed in immunotherapies : active and passive therapies. Passive immunotherapy is based on external immunity effectors delivered to the patient, like monoclonal antibodies or cytokines delivery. The main advantage of these therapies is that they do not rely on the immune system, for immunocompromised patients for example. In addition, they offer an immediate protection. However, this first generation of immunotherapies do not provide a long-lasting protection and their efficiency is limited by a lack of specificity toward the patient tumor antigen. Active immunotherapy relies on providing a specific information to make the immune system differentiate tumor-associated antigens (TAAs) from normal cells antigens. In cancer, TAAs are recognized as self-proteins by the immune system and do not cause T cell response. The objective of active immunotherapy is to break this tolerance by eliciting a CD8+ response against specific TAAs. Advantages of active immunotherapy include the induction of a long immune response with an immunological memory, and many any vectors available for induction according to the cell type targeted. Active Immunotherapies are essentially targeted therapies, but they are not personalized to the patient TAA. The main limitation for personalized active immunotherapy are development costs. One of the first immunotherapy approved against melanoma, Yervoy, cost in average 40,000$ a month and is not specific (6). Immunotherapies more specific and based on DCs, like Provenge®, are even more expensive with 93,000$ for each treatment (7), because DCs induction is an ex vivo labor-intensive process. In the case of Provenge®, patients must match the prostate tumor antigen PAP in order to qualify for this therapy. High production costs prevent these active immunotherapies to be adapted to the patient features, limiting the therapeutic outcome. To cut down costs and production time while improving efficiency, we created a yeast targeting DC in vivo, based on the non-pathogenic baker yeast S. cerevisiae. Synthetic biology transforms living organisms into engineerable chassis with a bottom-up strategy. The bottom-up approach allows sub-parts assembling to create complex systems with new features. Our living chassis takes advantage of this approach to make personalized medicine a reality, with a scalable cancer therapy. The standardized chassis targeting DC is personalized to the patient tumor antigen introduced in the form of plasmid in the chassis.
What should this page contain?
- A clear and concise description of your project.
- A detailed explanation of why your team chose to work on this particular project.
- References and sources to document your research.
- Use illustrations and other visual resources to explain your project.
Advice on writing your Project Description
We encourage you to put up a lot of information and content on your wiki, but we also encourage you to include summaries as much as possible. If you think of the sections in your project description as the sections in a publication, you should try to be consist, accurate and unambiguous in your achievements.
Judges like to read your wiki and know exactly what you have achieved. This is how you should think about these sections; from the point of view of the judge evaluating you at the end of the year.
References
iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you though about your project and what works inspired you.
Inspiration
See how other teams have described and presented their projects:
Our project is divided in 4 main wet lab sub-projects:
Project 1
A small text to explain the project!
Learn more!
Project 2
A small text to explain the project!
Learn more!
Project 3
A small text to explain the project!
Learn more!
Project 4
A small text to explain the project!
Learn more!
To top